Patients who continued to receive pembrolizumab-based therapy after disease progression had longer overall survival than patients who stopped receiving pembrolizumab-based therapy.

Taxane chemotherapy is unable to sensitize prostate cancer to immune checkpoint inhibitors, resulting in another negative trial with immunotherapy in prostate cancer,” said Andrea Necchi, MD.

Five-year data from the KEYNOTE-048 trial support the use of pembrolizumab and pembrolizumab-chemotherapy as standards of care, researchers wrote.

Summit Therapeutics' ivonescimab shows potential in cancer treatment, but high risks and valuation concerns suggest caution.

Bicara Therapeutics shows potential to reshape cancer care with ficerafusp alfa and robust funding post-IPO. Find out why ...

The US Food and Drug Administration (FDA) has granted clearance to CureVac's investigational new drug application (IND) for ...

Enriqueta Felip, MD, PhD, discusses the 3475A-D77 trial of subcutaneous pembrolizumab vs intravenous pembrolizumab plus chemotherapy in metastatic NSCLC.

The precise use of immunotherapy agents in locally advanced head and neck squamous cell carcinoma has not been clearly ...

Urothelium is the term for the mucous membrane that lines the urinary tract. This includes the renal pelvis, ureter, urinary ...

The addition of pembrolizumab to chemoradiotherapy improved PFS and OS for women with high-risk, locally advanced cervical cancer. The safety profile appeared consistent with that of the ...

Merck, known as MSD outside of the United States and Canada, announced the first data presentation from the pivotal 3475A-D77 phase 3 trial, evaluating the subcutaneous administration of pembrolizumab ...

There is currently no strong evidence that additional immune therapy benefits patients with renal cell carcinoma who were ...